Clinical Trial Update: The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports results from the XENERA-1 study evaluating Xentuzumab in combination with Everolimus and Exemestane in women with hormone rece…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Aromasin (exemestane)
• Xentuzumab (Xentuzumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-09-29